



Sheet 1 of 3

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0331/ AM100212(CON)	Application No. 10/661,182
		Applicant Megan Tran, et al.	
		Filing Date September 12, 2003	Group <u>1625</u> Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<u>SA</u>	1	Birch, A.M., "N-substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D <sub>2</sub> antagonists/5-HT <sub>1A</sub> partial agonists with potential as atypical antipsychotic agents," <i>J. Med. Chem.</i> , <b>1999</b> , 42, 3342-3355	
<u>SA</u>	2	Artigas, F., et al., "Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors," <i>Arch. Gen. Psychiatry</i> , <b>1994</b> , 248-251	
<u>SA</u>	3	Blier, P., et al., "Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression," <i>J. of Clinical Psychopharmacology</i> , <b>1995</b> , 15(3), 217-222	
*	4	<del>Bundgaard, (Ed.), Design of Prodrugs, Elsevier, 1985</del>	
<u>SA</u>	5	Bundgaard, H., et al., "(C) Means to enhance penetration; (1) Prodrugs as a means to improve the delivery of peptide drugs," <i>Advanced Drug Delivery Reviews</i> , <b>1992</b> , 8, 1-38	
*	6	<del>Bundgaard, J. of Pharmaceutical Sciences, 1988, 7(285 et seq.)</del>	
<u>SA</u>	7	Bundgaard, H., "Design and Application of Prodrugs," <i>Textbook of Drug Design and Development</i> , Krogsgaard-Larsen, P., et al. (Eds.), <b>1991</b> , Chap. 5, 114-123	
*	8	<del>Eliel, E.L., Stereochemistry of Carbon Compounds, McGraw-Hill, NY, 1962</del>	
<u>SA</u>	9	Hall, M.D., et al., "[ <sup>3</sup> H]8-hydroxy-2-(Di-n-Propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain," <i>J. Neurochem.</i> , <b>1985</b> , 44(6), 1685-1696	
*	10	<del>Higuchi, et al. (Eds.), Prodrugs as Novel Drug Delivery Systems, American Chemical Society, 1975</del>	
EXAMINER <u>SA</u>		DATE CONSIDERED <u>4/5/04</u>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0331/ AM100212(CON)	Application No. 10/661,182
		Applicant Megan Tran, et al.	
		Filing Date September 12, 2003	Group Not Yet Assigned <i>1625</i>
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
*	11	<del>Jacques, et al., Enantiomers, Racemates and Resolutions, Wiley-Interscience, NY, 1981</del>	
<i>SA</i>	12	Lazareno, S., et al., "Pharmacological characterization of acetylcholine-stimulated [ <sup>35</sup> S]-GYPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies," <i>Br. J. Pharmacol.</i> , <b>1993</b> , <i>109</i> , 1120-1127	
<i>SA</i>	13	Perez, V., "Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment," <i>The Lancet</i> , <b>1997</b> , <i>349</i> , 1594-1597	
*	14	<del>Remington's Pharmaceutical Sciences, 17<sup>th</sup> Ed., Gennaro, A.R. (Ed.), Mack Publishing Company, Easton, PA, 1985</del>	
<i>SA</i>	15	Tome, M.B., et al., "Serotonergic autoreceptor blockage in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol," <i>J. Affect Disord.</i> , <b>1997</b> , <i>44</i> , 101-109	
<i>SA</i>	16	Tome, M.B., et al., "Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency," <i>Int. Clin. Psychopharmacol.</i> , <b>1997</b> , <i>12</i> , 81-89	
*	17	<del>Widder, et al. (Eds.), Methods in Enzymology, Academic Press, 1985, Vol. 4</del>	
<i>SA</i>	18	Wilen, S.H., et al., "Strategies in optical resolutions," Tetrahedron Report Number 38, <i>Tetrahedron</i> , <b>1977</b> , <i>33</i> , 2725-2736	
<i>SA</i>	19	Wilen, S.H., "Tables of Resolving Agents and Optical Resolutions," <i>Univ. of Notre Dame Press, Notre Dame, IN</i> , E.L. Eliel (Ed.), <b>1972</b> , page 268-298	
EXAMINER <i>SA</i>		DATE CONSIDERED <i>4/5/04</i>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



Sheet 3 of 3

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0331/ AM100212(CON)	Application No. 10/661,182
	Applicant Megan Tran, et al.	
	Filing Date September 12, 2003	Group <i>1625</i> <del>Not Yet Assigned</del>
	Confirmation No. Not Yet Assigned	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
<i>SH</i>	20	5,468,767	11/21/95	Cipollina, et al.		
	21	5,532,241	07/02/96	Bottcher, et al.		
	22	5,741,789	04/21/98	Hibschman, et al.		
	23	5,750,724	05/12/98	Kang, et al.		
	24	5,869,490	02/09/99	Stack		
	25	5,977,106	11/02/99	Patoiseau, et al.		
<i>SH</i>	26	2002/01843355 A1	12/5/02	Tran, et al.	514	302

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
<i>SH</i>	27	WO 95/07274	03/16/95	PCT		
	28	WO 96/24596	08/15/96	PCT		
	29	WO 99/05140	02/04/99	PCT		
	30	WO 01/14330	03/01/01	PCT		
	31	WO 01/49680	07/12/01	PCT		
<i>SH</i>	32	0 559 285	09/08/93	EPO		

<b>EXAMINER</b> <i>Sh Huang</i>	<b>DATE CONSIDERED</b> <i>2/5/04</i>
---------------------------------	--------------------------------------